公募基金方面，本期较上一季未再披露的公募基金共计2491个，主要包括华夏核心科技6个月定开混合 A、华夏兴和混合A、华夏线上经济主题精选混合、华夏兴华混合A、华安智能生活混合A等。 外资态度来看，本期较上一季度新披露的外资机构有 1 家 ，即Grand Begonia Limited Partnership。本期 较上一季未再披露的外资机构即XJ Champion HK Limited。 2025年10月31日，威高血净(603014.SH)发布2025年第三季报。截至2025年10月30日，共有61个机构投 资者披露持有威高血净A股股份，合计持股量达3.56亿股，占威高血净总股本的85.16%。其中，前十大 机构投资者包括威高集团有限公司、山东威高集团医用高分子制品股份有限公司、威海凯德信息技术中 心(有限合伙)、山东威高血液净化制品股份有限公司未确认持有人证券专用账户、Grand Begonia Limited Partnership、Rosy Vigor Asia L.P.、上海华晟优格股权投资管理有限公司-厦门铧兴领沛创业投资 合伙企业(有限合伙)、上海华晟优格股权投资管理有限公司-天津华兴志凯股权投 ...

Company Overview - Weigao Blood Products (SH 603014) announced the convening of its 16th meeting of the second board of directors on October 29, 2025, to review the proposal for the company's Q3 2025 report [1] Financial Performance - For the first half of 2025, Weigao Blood Products reported a revenue composition where consumables accounted for 77.55%, equipment accounted for 18.25%, other businesses accounted for 2.35%, and other categories accounted for 1.85% [1]

Core Viewpoint - Weigao Blood Purification is a leading platform enterprise in the domestic blood purification field, with a complete product matrix and the highest market share in core products [1][6]. Group 1: Business Performance - In Q3 2025, Weigao Blood Purification reported revenue of 2.736 billion yuan, ranking 7th in the industry [2]. - The company's net profit for the same period was 341 million yuan, ranking 11th in the industry [2]. - The main business composition includes consumables at 1.369 billion yuan (77.55%), equipment at 322 million yuan (18.25%), and other revenues at 41.5142 million yuan (2.35%) [2]. Group 2: Financial Ratios - As of Q3 2025, the company's debt-to-asset ratio was 17.55%, lower than the industry average of 23.66% [3]. - The gross profit margin for the same period was 40.69%, which is below the industry average of 48.78% [3]. Group 3: Shareholder Information - As of September 30, 2025, the number of A-share shareholders decreased by 20.95% to 24,800 [5]. - The average number of circulating A-shares held per shareholder increased by 26.51% to 1,535.5 [5]. Group 4: Future Outlook - The company plans to invest IPO proceeds into intelligent production and is considering acquiring 100% of Weigao Purui in 2025 [5]. - The company is expected to benefit from a recovery in equipment procurement demand and market expansion, with projected net profits of 499 million, 552 million, and 608 million yuan for 2025-2027 [5]. - The estimated price-to-earnings ratio for 2026 is set at 34X, with a target price of 44.91 yuan [5]. Group 5: Market Position - Weigao Blood Purification holds the highest market share in the blood dialysis and blood dialysis tubing markets in China [6]. - The treatment penetration rate for ESRD patients in China is increasing, indicating a broad market outlook [6].

格隆汇10月30日丨威高血净(603014.SH)发布三季报，2025年前三季度实现营业总收入27.36亿元，同比 增长3.45%；归属母公司股东净利润3.41亿元，同比增长7.92%；基本每股收益为0.85元。 ...

证券代码：603014 证券简称：威高血净 公告编号：2025-037 山东威高血液净化制品股份有限公司 重要内容提示： ●委托理财金额：任一时点使用资金不超过 20 亿元人民币。 ●委托理财投资类型：购买金融机构发行的安全性高、流动性好的理财产品。 ●委托理财期限：自董事会审议通过之日起不超过 12 个月。 山东威高血液净化制品股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日 召开第二届董事会第十六次会议审议通过了《关于使用自有闲置资金购买理财产品 的议案》。董事会同意公司在任一时点使用不超过 20 亿元的总额度下，以自有闲置 资金购买理财产品，具体公告如下： 关于使用自有闲置资金购买理财产品的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 四、敏感性分析 一、理财目的 为了提高资金使用效率，增加资金运营收益，公司拟在不影响正常生产经营的 情况下，合理利用闲置自有资金购买金融机构发行的安全性高、流动性好的理财产 品。本委托理财不构成关联交易。 二、理财品种 公司拟投资购买的理财产品为金融机构发行的安 ...

证券代码：603014 证券简称：威高血净 公告编号：2025-036 山东威高血液净化制品股份有限公司 关于增加注册资本及修改《公司章程》的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 山东威高血液净化制品股份有限公司（以下简称"公司"）于 2025 年 10 月 29 日召开第二届董事会第十六次会议审议通过了《关于增加注册资本及修改公司章程 的议案》。现将相关情况公告如下： 一、增加注册资本情况 2025 年 10 月 31 日 根据安永华明会计师事务所（特殊普通合伙）出具的编号为安永华明（2025） 验字第 70065792_J03 号《验资报告》，截至 2025 年 9 月 19 日，公司已收到 120 名 股权激励对象以货币资金缴纳的限制性股票认购款合计人民币 125,737,200 元。其中 计入股本人民币 6,360,000 元，计入资本公积（股本溢价）人民币 119,377,200 元。 变更后的累计注册资本为人民币 417,754,066 元，股本为人民币 417,754,066 元。 中国证券登记结 ...

Financial Performance - The company's operating revenue for the third quarter was ¥971,372,306.12, a decrease of 4.65% compared to the same period last year[4] - The total profit for the quarter was ¥142,242,922.85, reflecting an increase of 7.55% year-over-year[4] - Net profit attributable to shareholders was ¥120,540,708.48, up by 4.15% compared to the same quarter last year[4] - Total operating revenue for the first three quarters of 2025 reached ¥2,736,052,670.24, a 3.46% increase from ¥2,644,762,353.56 in the same period of 2024[21] - Net profit for the first three quarters of 2025 was ¥340,778,059.35, representing a 7.93% increase compared to ¥315,755,268.67 in 2024[22] - Earnings per share remained stable at ¥0.85 for both 2025 and 2024[23] Cash Flow - The net cash flow from operating activities for the year-to-date period was ¥485,340,683.74, an increase of 63.33%[5][11] - The net cash flow from operating activities increased to $485.34 million from $297.15 million, representing a growth of approximately 63.2% year-over-year[24] - Cash inflow from operating activities totaled ¥2,926,721,100.30, slightly up from ¥2,924,762,172.23 in the previous year[23] - Cash inflow from investment activities surged to $4.87 billion, up from $1.91 billion, indicating a significant increase of about 154.5%[24] - The net cash flow from investment activities was negative at -$760.94 million, compared to -$256.99 million, reflecting a decline in investment returns[24] - Cash inflow from financing activities amounted to $1.22 billion, with a net cash flow of $1.11 billion, a substantial improvement from a net outflow of -$14.10 million[24] - The total cash flow for the period was a net increase of $836.77 million, compared to $24.40 million in the prior year, reflecting a significant improvement[24] Assets and Liabilities - Total assets at the end of the reporting period reached ¥8,468,254,452.63, representing a growth of 21.15% from the end of the previous year[5] - The company's current assets totaled CNY 4.51 billion, up from CNY 2.98 billion, indicating a significant increase of approximately 51.3%[16] - Total liabilities increased to ¥1,486,185,982.21, up from ¥1,393,369,525.16, reflecting a growth of 6.67%[18] - The equity attributable to shareholders increased to ¥6,982,068,470.42, a rise of 24.75% year-over-year[5] - Total equity attributable to shareholders rose to ¥6,982,068,470.42, an increase of 24.74% from ¥5,596,777,565.36[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 24,821[12] - The largest shareholder, Weigao Group Co., Ltd., holds 41.11% of the shares, totaling 171,755,909 shares[13] - The company reported a total of 10,485,839 shares held in an unconfirmed account, pending certification for foreign shareholders[15] - There were no changes in the participation of major shareholders in margin financing and securities lending activities[15] Expenses and Other Income - Total operating costs increased to ¥2,345,783,937.85, up 3.05% from ¥2,276,301,286.47 year-over-year[21] - Research and development expenses decreased to ¥105,705,786.32 from ¥121,914,072.63, a reduction of 13.27%[21] - The company reported a decrease in financial expenses, with a net expense of ¥508,267.91 compared to a net income of ¥2,209,726.54 in the previous year[21] - Other income decreased significantly to ¥17,076,905.61 from ¥32,718,401.80, a decline of 47.8%[21] Inventory and Receivables - The accounts receivable stood at CNY 886.48 million, slightly down from CNY 899.70 million, showing a decrease of about 1.3%[16] - Inventory increased to CNY 819.73 million from CNY 757.07 million, marking an increase of approximately 8.3%[16] Changes in Accounting Standards - The company will not apply new accounting standards starting from 2025, as per the announcement[25]

证券代码：603014 证券简称：威高血净 公告编号：2025-035 山东威高血液净化制品股份有限公司 第二届董事会第十六次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 一、董事会会议召开情况 山东威高血液净化制品股份有限公司（以下简称"威高血净"或"公司"）第二届董 事会第十六次会议于 2025 年 10 月 29 日以现场和通讯相结合的方式在公司会议室召 开，会议通知于 2025 年 10 月 29 日通过通讯方式送达全体董事。本次会议由董事长 宋修山召集并主持，会议应出席董事 9 人，实际出席董事 9 人；公司部分高级管理 人员列席了本次会议。本次会议的召集、召开和表决程序符合《中华人民共和国公 司法》等法律、法规、部门规章、规范性文件和《公司章程》的有关规定。 二、董事会会议审议情况 具体内容详见公司同日刊登于上海证券交易所网站（www.sse.com.cn）及公司指 定信息披露媒体的《山东威高血液净化制品股份有限公司 2025 年第三季度报告》。 表决结果：9 票同意，0 票弃权，0 票反对。 （二 ...

Summary of Key Points from the Conference Call Industry Overview - The blood purification industry is experiencing significant growth driven by domestic substitution and centralized procurement policies, benefiting companies like Shanwaishan and Weigao Blood Purification, especially in critical care during the pandemic [1][2][6] - The market for blood purification devices and consumables is expected to continue expanding, with the dialysis machine market projected to reach tens of billions by 2030, supported by increased medical insurance coverage and improved living standards [1][9] Key Trends and Insights - **Domestic Substitution and Centralized Procurement**: Domestic companies are gaining market share due to favorable policies, with notable performances from Shanwaishan and Weigao Blood Purification [2][4] - **International Expansion**: Companies like San Aisi and Baolait are showing potential in emerging markets such as South America and Southeast Asia, with significant expected growth in export volumes [1][3][5] - **Full Industry Chain Development**: Companies are focusing on developing their own consumables alongside devices to enhance competitiveness, as seen with Shanwaishan's self-developed consumables [1][7] - **Strong Product Competitiveness**: Companies with strong single product competitiveness, such as Tianyi Medical and its acquisition of the CRT business, are expected to see growth despite centralized procurement trends [1][7] Company-Specific Insights - **Shanwaishan**: Achieved nearly 30% revenue growth in the first half of 2025, with a focus on expanding its product range and international market presence [15][16] - **Dingwen**: Reported a 10% revenue growth in the first half of 2025, with expectations of a 50% increase in overseas revenue due to international expansion efforts [18] - **Jianfa**: Dominates the perfusion device market with over 80% market share, but faces challenges in maintaining growth after a significant increase in sales during the pandemic [21] - **Tianyi Medical**: Anticipates over 20% revenue growth this year, supported by acquisitions and new factory developments [28][29] Market Dynamics - The blood purification market is characterized by a compound annual growth rate of approximately 5% in patient demand, with a double-digit growth rate in market size [2][9] - The dialysis machine market is currently valued at around 3 billion yuan, with expectations to grow significantly by 2030 [9] - The introduction of joint charging policies for blood perfusion and dialysis is expected to positively impact industry performance [23] Competitive Landscape - Domestic manufacturers are increasingly competitive against international players, with companies like Shanwaishan and Tianyi Medical showing strong international revenue growth [13][14] - The centralized procurement trend may lead to a decline in market share for overseas manufacturers, while domestic firms like Samsung and Shanwaishan are expected to gain [4][10] Conclusion - The blood purification industry is poised for robust growth, driven by domestic substitution, international expansion, and full industry chain development strategies. Companies that adapt to these trends and enhance their product offerings are likely to succeed in this evolving market landscape [1][12][22]

Core Viewpoint - The company is planning to issue shares to acquire 100% equity of Weigao Purui Pharmaceutical Packaging Co., Ltd, which will become a wholly-owned subsidiary after the transaction is completed [1][2]. Group 1: Transaction Details - The transaction is currently in the planning stage, and no formal agreement has been signed yet [2]. - The company has applied for a stock suspension starting from October 20, 2025, to prevent significant impacts on its stock price [1][2]. - The transaction requires approval from the company's board, shareholders, and relevant regulatory authorities before it can be officially implemented [2]. Group 2: Investor Communication - The company emphasizes the importance of maintaining investor interests and will adhere to legal and regulatory requirements during the transaction process [2]. - The company will disclose information regarding the transaction's progress and will apply for stock resumption once the relevant matters are confirmed [2].